Literature DB >> 25103368

Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M.

Meng-Ping Hsu1, Ricardo Frausto, Stefan Rose-John, Iain L Campbell.   

Abstract

The interleukin (IL)-6/gp130 family of cytokines (e.g., IL-6, IL-11, leukemia inhibitory factor (LIF) and oncostatin M (OSM)) play important roles in the central nervous system (CNS) during neuroinflammation and neurodevelopment. However, little is known regarding the responses by astroglia and microglia to this family of cytokines. Here the expression of the IL-6/gp130 cytokine receptors and subsequent signal pathway activation was examined in murine astrocytes and microglia in vitro. Astrocytes had high levels of OSMR mRNA while lower levels of IL-6R, LIFR and IL-11R mRNAs were also present. In comparison, in microglia there was no detectable OSMR mRNA, higher levels of IL-6R mRNA and lower levels of the LIFR and IL-11R mRNAs. The OSMR protein was present in astrocytes but was undetectable in microglia. Conversely, the IL-6R protein was present in microglia but not detectable in astrocytes. In astrocytes but not microglia, phosphorylation of STAT1 and STAT3 occurred in response to OSM, whereas both microglia and astrocytes responded to hyper-IL-6 (IL-6 linked to the soluble IL-6 receptor). Finally, in both microglia and astrocytes, OSM failed to activate NFκB or induce iNOS and nitrite production. We conclude: (1) notable differences exist in the expression of receptors utilized by the IL-6/gp130 family of cytokines in astrocytes and microglia, and (2) the findings provide a molecular basis for the differential response to OSM by astrocytes versus microglia and demonstrate a fundamental means for achieving cellular specificity in the response of these glial cells to this cytokine.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  gp130; receptor; signal transducers and activators of transcription; signal transduction

Mesh:

Substances:

Year:  2014        PMID: 25103368     DOI: 10.1002/glia.22739

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  22 in total

1.  Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination.

Authors:  Evelien Houben; Kris Janssens; Doryssa Hermans; Jennifer Vandooren; Chris Van den Haute; Melissa Schepers; Tim Vanmierlo; Ivo Lambrichts; Jack van Horssen; Veerle Baekelandt; Ghislain Opdenakker; Wia Baron; Bieke Broux; Helena Slaets; Niels Hellings
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

Review 2.  Cerebral Aneurysm and Interleukin-6: a Key Player in Aneurysm Generation and Rupture or Just One of the Multiple Factors?

Authors:  Molly Monsour; Davide Marco Croci; Basil E Grüter; Philipp Taussky; Serge Marbacher; Siviero Agazzi
Journal:  Transl Stroke Res       Date:  2022-08-31       Impact factor: 6.800

3.  Uric Acid Neuroprotection Associated to IL-6/STAT3 Signaling Pathway Activation in Rat Ischemic Stroke.

Authors:  Alicia Aliena-Valero; Sergio Rius-Pérez; Júlia Baixauli-Martín; Germán Torregrosa; Ángel Chamorro; Salvador Pérez; Juan B Salom
Journal:  Mol Neurobiol       Date:  2020-09-22       Impact factor: 5.590

4.  Involvement of Spinal IL-6 Trans-Signaling in the Induction of Hyperexcitability of Deep Dorsal Horn Neurons by Spinal Tumor Necrosis Factor-Alpha.

Authors:  Christian König; Eric Morch; Annett Eitner; Christian Möller; Brian Turnquist; Hans-Georg Schaible; Andrea Ebersberger
Journal:  J Neurosci       Date:  2016-09-21       Impact factor: 6.167

5.  Transcriptomics identifies STAT3 as a key regulator of hippocampal gene expression and anhedonia during withdrawal from chronic alcohol exposure.

Authors:  Wei-Yang Chen; Hu Chen; Kana Hamada; Eleonora Gatta; Ying Chen; Huaibo Zhang; Jenny Drnevich; Harish R Krishnan; Mark Maienschein-Cline; Dennis R Grayson; Subhash C Pandey; Amy W Lasek
Journal:  Transl Psychiatry       Date:  2021-05-20       Impact factor: 6.222

6.  Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells.

Authors:  Ryan C Turner; Zachary J Naser; Brandon P Lucke-Wold; Aric F Logsdon; Reyna L Vangilder; Rae R Matsumoto; Jason D Huber; Charles L Rosen
Journal:  Neuroimmunol Neuroinflamm       Date:  2017-01-20

Review 7.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

8.  SorLA in Interleukin-6 Signaling and Turnover.

Authors:  Jakob Vejby Larsen; Claus Munck Petersen
Journal:  Mol Cell Biol       Date:  2017-05-16       Impact factor: 4.272

9.  Oncostatin M Confers Neuroprotection against Ischemic Stroke.

Authors:  Sen Guo; Zuo-Zhi Li; Jun Gong; Mei Xiang; Peng Zhang; Guang-Nian Zhao; Mingchang Li; Ankang Zheng; Xueyong Zhu; Hao Lei; Tanaka Minoru; Hongliang Li
Journal:  J Neurosci       Date:  2015-08-26       Impact factor: 6.167

10.  Oncostatin M promotes excitotoxicity by inhibiting glutamate uptake in astrocytes: implications in HIV-associated neurotoxicity.

Authors:  Shamsudheen Moidunny; Marco Matos; Evelyn Wesseling; Santanu Banerjee; David J Volsky; Rodrigo A Cunha; Paula Agostinho; Hendrikus W Boddeke; Sabita Roy
Journal:  J Neuroinflammation       Date:  2016-06-10       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.